Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

5.230 +0.270 (+5.44%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	864,658
Open	4.970
Bid (Size)	5.170 (200)
Ask (Size)	5.300 (500)
Prev. Close	4.960
Today's Range	4.950 - 5.300
52wk Range	1.140 - 7.200
Shares Outstanding	58,576,350
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

November 13, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

November 11, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Performance

YTD	+0.2%	+0.2%
1 Month	N/A	N/A
3 Month	-9.4%	-9.4%
6 Month	+137.7%	+137.7%
1 Year	+5.2%	+5.2%

More News

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

November 06, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial ↗

October 28, 2025

Via Stocktwits

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

October 28, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗

October 10, 2025

Via Benzinga

4 Biotech Stocks Seeing Explosive Momentum Gains ↗

October 07, 2025

Via Benzinga

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 03, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

August 28, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

August 19, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 06, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

July 24, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

July 17, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

June 26, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

June 17, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 29, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

May 18, 2025

From Pomerantz LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

May 14, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX

May 13, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

May 09, 2025

From Pomerantz LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

May 07, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 06, 2025

Via Benzinga

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 05, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 05, 2025

From Aldeyra Therapeutics, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

May 05, 2025

From Pomerantz LLP

Via GlobeNewswire

Frequently Asked Questions

Is Aldeyra Therapeutics, Inc. - Common Stock publicly traded?

Yes, Aldeyra Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Aldeyra Therapeutics, Inc. - Common Stock trade on?

Aldeyra Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock?

The ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock is ALDX on the Nasdaq Stock Market

What is the current price of Aldeyra Therapeutics, Inc. - Common Stock?

The current price of Aldeyra Therapeutics, Inc. - Common Stock is 5.230

When was Aldeyra Therapeutics, Inc. - Common Stock last traded?

The last trade of Aldeyra Therapeutics, Inc. - Common Stock was at 11/24/25 04:00 PM ET

What is the market capitalization of Aldeyra Therapeutics, Inc. - Common Stock?

The market capitalization of Aldeyra Therapeutics, Inc. - Common Stock is 306.35M

How many shares of Aldeyra Therapeutics, Inc. - Common Stock are outstanding?

Aldeyra Therapeutics, Inc. - Common Stock has 306M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.